USP7/HAUSP promotes the Sequence-Specific DNA Binding Activity of p53

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Sarkari, Feroz ^a   Sheng, Yi ^b   Frappier, Lori ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN HAUSP; PROTEIN P21; PROTEIN P53; PROTEIN USP7; PROTEINASE; UNCLASSIFIED DRUG; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN PURIFICATION; REGULATORY MECHANISM; UBIQUITINATION; BINDING SITE; CHEMISTRY; GENETICS; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; CELL LINE; DNA; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 77958566202     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013040     Document Type: Article

References (41)

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310.
2. Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7: 165-168.
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
4. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
5. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
6. Ho J, Benchimol S (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10: 404-408.
7. Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127-1130.
8. Soussi T, Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312.
9. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
10. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
11. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, et al. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841.
12. Takenaka I, Morin F, Seizinger BR, Kley N (1995) Regulation of the sequencespecific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270: 5405-5411.
13. Wang Y, Prives C (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91.
14. Muller-Tiemann BF, Halazonetis TD, Elting JJ (1998) Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc Natl Acad Sci U S A 95: 6079-6084.
15. Halazonetis TD, Davis LJ, Kandil AN (1993) Wild-type p53 adopts a 'mutant'- like conformation when bound to DNA. EMBO J 12: 1021-1028.
16. Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, et al. (2001) Latent and active p53 are identical in conformation. Nat Struct Biol 8: 756-760.
17. Espinosa JM, Emerson BM (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8: 57-69.
18. McKinney K, Prives C (2002) Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with highmobility group 1 protein. Mol Cell Biol 22: 6797-6808.
19. Gohler T, Reimann M, Cherny D, Walter K, Warnecke G, et al. (2002) Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J Biol Chem 277: 41192-41203.
20. McKinney K, Mattia M, Gottifredi V, Prives C (2004) p53 linear diffusion along DNA requires its C terminus. Mol Cell 16: 413-424.
21. Tafvizi A, Huang F, Leith JS, Fersht AR, Mirny LA, et al. (2008) Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys J 95: L01-03.
22. Shan J, Brooks C, Kon N, Li M, Gu W (2008) Dissecting roles of ubiquitination in the p53 pathway. Ernst Schering Found Symp Proc. pp 127-136.
23. Hu M, Li P, Li M, Li W, Yao T, et al. (2002) Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111: 1041-1054.
24. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, et al. (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653.
25. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, et al. (2005) Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18: 25-36.
26. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, et al. (2006) Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol 13: 285-291.
27. Hu M, Gu L, Li M, Jeffrey PD, Gu W, et al. (2006) Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol 4: e27.
28. Meredith M, Orr A, Everett R (1994) Herpes simplex virus type 1 immediateearly protein Vmw110 binds strongly and specifically to a 135-kDa cellular protein. Virology 200: 457-469.
29. Holowaty MN, Zeghouf M, Wu H, Tellam J, Athanasopoulos V, et al. (2003) Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 278: 29987-29994.
30. Sivachandran N, Sarkari F, Frappier L (2008) Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog 4: e1000170.
31. Rickinson AEK (2001) Epstein-Barr Virus. In: HowleyDMKaPM, ed. Fields Virology. Philadelphia: Lippincott Williams and Wilkins. pp 22575-22627.
32. Sarkari F, Sanchez-Alcaraz T, Wang S, Holowaty MN, Sheng Y, et al. (2009) EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathog 5: e1000624.
33. Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L (2003) Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem 278: 47753-47761.
34. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, et al. (2006) FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 8: 1064-1073.
35. Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137.
36. Appella E, Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772.
37. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
38. Sarkari F, Wang X, Nguyen T, Frappier L (2010) The Herpesvirus Associated Ubiquitin Specific Protease, USP7, is a Negative Regulator of PML Proteins and PML Nuclear Bodies. Submitted.
39. Wang S, Frappier L (2009) Nucleosome assembly proteins bind to Epstein-Barr virus nuclear antigen 1 and affect its functions in DNA replication and transcriptional activation. J Virol 83: 11704-11714.
40. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
41. Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ (1998) Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 12: 2102-2107.